Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung

Biol Blood Marrow Transplant. 2015 Jun;21(6):1127-31. doi: 10.1016/j.bbmt.2015.02.006. Epub 2015 Feb 14.

Abstract

Bronchiolitis obliterans syndrome (BOS) is a significant post-transplant complication with low survival. BOS stage 0p (BOS 0p) is a parameter detected on pulmonary function tests (PFTs) after lung transplantation to identify patients at risk to develop BOS. We performed a retrospective study on 442 patients who underwent allogeneic stem cell transplant from 2007 to 2011 to evaluate whether development of BOS 0p is a risk factor in this population for BOS. Patients who met criteria for BOS 0p were significantly more likely to develop BOS (hazard ratio [HR], 3.22; P < .001). BOS 0p was significantly associated with a history of lung disease pretransplant (HR, 2.48; P = .001) and chronic graft-versus-host disease (GVHD) outside the lung post-transplant (HR, 23; P < .001). Finally, BOS 0p criteria were adequately sensitive in predicting BOS (85%), with a high negative predictive value (98%). Our findings suggest a routine PFT screening strategy with the intent of detecting BOS 0p, especially among patients with prior lung disease and who developed chronic GVHD, could suitably identify an at-risk population for the development of BOS.

Keywords: BOS 0p; Bronchiolitis obliterans syndrome; Chronic GVHD.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Bronchiolitis Obliterans / diagnosis*
  • Bronchiolitis Obliterans / mortality
  • Bronchiolitis Obliterans / surgery
  • Bronchiolitis Obliterans / therapy
  • Female
  • Graft vs Host Disease / diagnosis*
  • Graft vs Host Disease / mortality
  • Graft vs Host Disease / surgery
  • Graft vs Host Disease / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lung / drug effects
  • Lung / immunology
  • Lung / pathology
  • Lung / surgery
  • Lung Transplantation*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myeloablative Agonists / therapeutic use
  • Predictive Value of Tests
  • Prognosis
  • Respiratory Function Tests
  • Retrospective Studies
  • Risk Factors
  • Siblings
  • Survival Analysis
  • Transplantation Conditioning*
  • Transplantation, Homologous
  • Unrelated Donors

Substances

  • Myeloablative Agonists